Abstract
Background: Ten percent of the population claims an allergy to penicillin, but 90% of these individuals are not allergic. Patients labeled as penicillin-allergic have higher medical costs, longer hospital stays, are more likely to be treated with broad-spectrum antibiotics, and develop drug-resistant bacterial infections. Most penicillin skin test reagents are not approved by the Food and drug Administration or readily available to evaluate patients labeled penicillin-allergic. Objective: To determine the negative predictive value (NPV) of the Penicillin Skin Test Kit containing the major allergenic determinant (penicilloyl polylysine), a minor determinant mixture (penicillin G, penicilloate, penilloate), and amoxicillin, produced according to Food and Drug Administration standards. Methods: This was a prospective, multicenter, open-label investigation of penicillin skin testing using the Penicillin Skin Test Kit. Skin test–negative subjects were challenged with 250 mg amoxicillin, whereas skin test–positive patients were not challenged. The primary end point was NPV of the Penicillin Skin Test Kit, defined as the percentage of subjects with negative skin test results who did not experience an IgE-dependent reaction within 72 hours of amoxicillin challenge. Results: In total, 455 patients with a history of penicillin allergy underwent skin testing and 63 (13.8%) had 1 or more positive test results; 65% of the positive test results were to the minor determinant mixture and/or amoxicillin alone. In the per protocol group of 373 skin test–negative subjects, 8 developed potential IgE-dependent reactions following oral amoxicillin challenge, translating to an NPV of 97.9% (95% CI, 95.8-99.1; P < .0001). All but 1 of the reactions was mild or moderate, and most subjects who required treatment received only antihistamines. Conclusions: The Penicillin Skin Test Kit, containing all relevant penicillin allergenic determinants, demonstrated very high NPV. Removal of a penicillin allergy label in a large majority of currently mislabeled patients has substantial personal and public health implications.
Original language | English |
---|---|
Pages (from-to) | 1876-1885.e3 |
Journal | Journal of Allergy and Clinical Immunology: In Practice |
Volume | 7 |
Issue number | 6 |
DOIs | |
State | Published - Jul 1 2019 |
Keywords
- Allergy
- Amoxicillin
- Penicillin
- Penicilloate
- Penicilloyl polylysine
- Penilloate
- Skin testing
Fingerprint
Dive into the research topics of 'Penicillin Allergy Evaluation: A Prospective, Multicenter, Open-Label Evaluation of a Comprehensive Penicillin Skin Test Kit'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, No. 6, 01.07.2019, p. 1876-1885.e3.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Penicillin Allergy Evaluation
T2 - A Prospective, Multicenter, Open-Label Evaluation of a Comprehensive Penicillin Skin Test Kit
AU - Solensky, Roland
AU - Jacobs, Joshua
AU - Lester, Mitchell
AU - Lieberman, Phillip
AU - McCafferty, F.
AU - Nilsson, Thomas
AU - Park, Miguel
AU - Schwarz, G.
AU - Soong, W.
AU - Wagelie-Steffen, Amy
AU - Wedner, H. James
AU - Weiss, Michael
AU - Windom, Hugh
AU - Tonascia, J.
AU - Yates, Katherine P.
AU - Mendelson, Louis M.
AU - Wolfe, J.
AU - Adkinson, N. Franklin
N1 - Funding Information: This study was funded by AllerQuest, LLC. AllerQuest was involved in study design, in analysis and interpretation of the data, in the writing of the report, and in the decision to submit the article for publication. AllerQuest was not directly involved in collection of the data.R. Solensky received research support from Stallergenes Greer (allergic rhinitis) and AstraZeneca (asthma) and provided expert witness testimony (drug allergy). J. Jacobs received grants and personal fees from Shire plc, CSL Behring, Novartis, AstraZeneca, Teva, Regeneron, and Sanofi Genzyme and grants from Biocrust and Genentech. G. Schwarz is on the speakers bureau for Teva, Shire, and Pfizer. W. Soong is involved with Regeneron as advisory board member and speaker, and in clinical trials research (asthma and atopic dermatitis); Teva as advisory board member and in clinical trials research (asthma); Astra-Zeneca as advisory board member and speaker, and in clinical trials research (asthma); AbbVie as consultant and in clinical trials research (atopic dermatitis); Pfizer in clinical trials research (atopic dermatitis); ALK as advisory board member (allergic rhinitis); Aimmune in clinical trials research (food allergy); Novartis in clinical trials research (asthma); Genentech in clinical trials research (asthma, nasal polyps, and urticaria); Leo in clinical trials research (atopic dermatitis); and GlaxoSmithKline in clinical trials research (nasal polyps). H. Windom received clinical trial support from Novartis, Teva, Astra-Zeneca, Aimmune, DBV, Theravance, West-Ward, Mylan, and Genentech. L. M. Mendelson is founder and officer of AllerQuest and has equity ownership of AllerQuest, which is the sponsor and funder of this research. J. Wolfe is founder and officer of AllerQuest; has equity ownership of AllerQuest, which is the sponsor and funder of this research; and has been involved in consultancy, speakers bureau, and/or clinical trials research for Afferent, Aimmune, Amphastar, Astra-Zeneca, Biota Pharma, Chiesi Pharma, Cipla Pharma, Glenmark, GlaxoSmithKline, Lupin, Menlo Pharma, Merck, Mylan, Nerre Therapeutics, Novartis, Pearl Therapeutics, Pharm Olam, Roxane Laboratories, Sanofi, Spirosure, Teva, 3M Pharma, Watson, and Zosano. N. F. Adkinson is founder and officer of AllerQuest and has equity ownership of AllerQuest, which is the sponsor and funder of this research. The rest of the authors declare that they have no relevant conflicts of interest. This study was funded by AllerQuest, LLC. AllerQuest was involved in study design, in analysis and interpretation of the data, in the writing of the report, and in the decision to submit the article for publication. AllerQuest was not directly involved in collection of the data. R. Solensky received research support from Stallergenes Greer (allergic rhinitis) and AstraZeneca (asthma) and provided expert witness testimony (drug allergy). J. Jacobs received grants and personal fees from Shire plc, CSL Behring, Novartis, AstraZeneca, Teva, Regeneron, and Sanofi Genzyme and grants from Biocrust and Genentech. G. Schwarz is on the speakers bureau for Teva, Shire, and Pfizer. W. Soong is involved with Regeneron as advisory board member and speaker, and in clinical trials research (asthma and atopic dermatitis); Teva as advisory board member and in clinical trials research (asthma); Astra-Zeneca as advisory board member and speaker, and in clinical trials research (asthma); AbbVie as consultant and in clinical trials research (atopic dermatitis); Pfizer in clinical trials research (atopic dermatitis); ALK as advisory board member (allergic rhinitis); Aimmune in clinical trials research (food allergy); Novartis in clinical trials research (asthma); Genentech in clinical trials research (asthma, nasal polyps, and urticaria); Leo in clinical trials research (atopic dermatitis); and GlaxoSmithKline in clinical trials research (nasal polyps). H. Windom received clinical trial support from Novartis, Teva, Astra-Zeneca, Aimmune, DBV, Theravance, West-Ward, Mylan, and Genentech. L. M. Mendelson is founder and officer of AllerQuest and has equity ownership of AllerQuest, which is the sponsor and funder of this research. J. Wolfe is founder and officer of AllerQuest; has equity ownership of AllerQuest, which is the sponsor and funder of this research; and has been involved in consultancy, speakers bureau, and/or clinical trials research for Afferent, Aimmune, Amphastar, Astra-Zeneca, Biota Pharma, Chiesi Pharma, Cipla Pharma, Glenmark, GlaxoSmithKline, Lupin, Menlo Pharma, Merck, Mylan, Nerre Therapeutics, Novartis, Pearl Therapeutics, Pharm Olam, Roxane Laboratories, Sanofi, Spirosure, Teva, 3M Pharma, Watson, and Zosano. N. F. Adkinson is founder and officer of AllerQuest and has equity ownership of AllerQuest, which is the sponsor and funder of this research. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This study was funded by AllerQuest , LLC . AllerQuest was involved in study design, in analysis and interpretation of the data, in the writing of the report, and in the decision to submit the article for publication. AllerQuest was not directly involved in collection of the data. Funding Information: This study was funded by AllerQuest, LLC. AllerQuest was involved in study design, in analysis and interpretation of the data, in the writing of the report, and in the decision to submit the article for publication. AllerQuest was not directly involved in collection of the data.R. Solensky received research support from Stallergenes Greer (allergic rhinitis) and AstraZeneca (asthma) and provided expert witness testimony (drug allergy). J. Jacobs received grants and personal fees from Shire plc, CSL Behring, Novartis, AstraZeneca, Teva, Regeneron, and Sanofi Genzyme and grants from Biocrust and Genentech. G. Schwarz is on the speakers bureau for Teva, Shire, and Pfizer. W. Soong is involved with Regeneron as advisory board member and speaker, and in clinical trials research (asthma and atopic dermatitis); Teva as advisory board member and in clinical trials research (asthma); Astra-Zeneca as advisory board member and speaker, and in clinical trials research (asthma); AbbVie as consultant and in clinical trials research (atopic dermatitis); Pfizer in clinical trials research (atopic dermatitis); ALK as advisory board member (allergic rhinitis); Aimmune in clinical trials research (food allergy); Novartis in clinical trials research (asthma); Genentech in clinical trials research (asthma, nasal polyps, and urticaria); Leo in clinical trials research (atopic dermatitis); and GlaxoSmithKline in clinical trials research (nasal polyps). H. Windom received clinical trial support from Novartis, Teva, Astra-Zeneca, Aimmune, DBV, Theravance, West-Ward, Mylan, and Genentech. L. M. Mendelson is founder and officer of AllerQuest and has equity ownership of AllerQuest, which is the sponsor and funder of this research. J. Wolfe is founder and officer of AllerQuest; has equity ownership of AllerQuest, which is the sponsor and funder of this research; and has been involved in consultancy, speakers bureau, and/or clinical trials research for Afferent, Aimmune, Amphastar, Astra-Zeneca, Biota Pharma, Chiesi Pharma, Cipla Pharma, Glenmark, GlaxoSmithKline, Lupin, Menlo Pharma, Merck, Mylan, Nerre Therapeutics, Novartis, Pearl Therapeutics, Pharm Olam, Roxane Laboratories, Sanofi, Spirosure, Teva, 3M Pharma, Watson, and Zosano. N. F. Adkinson is founder and officer of AllerQuest and has equity ownership of AllerQuest, which is the sponsor and funder of this research. The rest of the authors declare that they have no relevant conflicts of interest. Publisher Copyright: © 2019 American Academy of Allergy, Asthma & Immunology
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Background: Ten percent of the population claims an allergy to penicillin, but 90% of these individuals are not allergic. Patients labeled as penicillin-allergic have higher medical costs, longer hospital stays, are more likely to be treated with broad-spectrum antibiotics, and develop drug-resistant bacterial infections. Most penicillin skin test reagents are not approved by the Food and drug Administration or readily available to evaluate patients labeled penicillin-allergic. Objective: To determine the negative predictive value (NPV) of the Penicillin Skin Test Kit containing the major allergenic determinant (penicilloyl polylysine), a minor determinant mixture (penicillin G, penicilloate, penilloate), and amoxicillin, produced according to Food and Drug Administration standards. Methods: This was a prospective, multicenter, open-label investigation of penicillin skin testing using the Penicillin Skin Test Kit. Skin test–negative subjects were challenged with 250 mg amoxicillin, whereas skin test–positive patients were not challenged. The primary end point was NPV of the Penicillin Skin Test Kit, defined as the percentage of subjects with negative skin test results who did not experience an IgE-dependent reaction within 72 hours of amoxicillin challenge. Results: In total, 455 patients with a history of penicillin allergy underwent skin testing and 63 (13.8%) had 1 or more positive test results; 65% of the positive test results were to the minor determinant mixture and/or amoxicillin alone. In the per protocol group of 373 skin test–negative subjects, 8 developed potential IgE-dependent reactions following oral amoxicillin challenge, translating to an NPV of 97.9% (95% CI, 95.8-99.1; P < .0001). All but 1 of the reactions was mild or moderate, and most subjects who required treatment received only antihistamines. Conclusions: The Penicillin Skin Test Kit, containing all relevant penicillin allergenic determinants, demonstrated very high NPV. Removal of a penicillin allergy label in a large majority of currently mislabeled patients has substantial personal and public health implications.
AB - Background: Ten percent of the population claims an allergy to penicillin, but 90% of these individuals are not allergic. Patients labeled as penicillin-allergic have higher medical costs, longer hospital stays, are more likely to be treated with broad-spectrum antibiotics, and develop drug-resistant bacterial infections. Most penicillin skin test reagents are not approved by the Food and drug Administration or readily available to evaluate patients labeled penicillin-allergic. Objective: To determine the negative predictive value (NPV) of the Penicillin Skin Test Kit containing the major allergenic determinant (penicilloyl polylysine), a minor determinant mixture (penicillin G, penicilloate, penilloate), and amoxicillin, produced according to Food and Drug Administration standards. Methods: This was a prospective, multicenter, open-label investigation of penicillin skin testing using the Penicillin Skin Test Kit. Skin test–negative subjects were challenged with 250 mg amoxicillin, whereas skin test–positive patients were not challenged. The primary end point was NPV of the Penicillin Skin Test Kit, defined as the percentage of subjects with negative skin test results who did not experience an IgE-dependent reaction within 72 hours of amoxicillin challenge. Results: In total, 455 patients with a history of penicillin allergy underwent skin testing and 63 (13.8%) had 1 or more positive test results; 65% of the positive test results were to the minor determinant mixture and/or amoxicillin alone. In the per protocol group of 373 skin test–negative subjects, 8 developed potential IgE-dependent reactions following oral amoxicillin challenge, translating to an NPV of 97.9% (95% CI, 95.8-99.1; P < .0001). All but 1 of the reactions was mild or moderate, and most subjects who required treatment received only antihistamines. Conclusions: The Penicillin Skin Test Kit, containing all relevant penicillin allergenic determinants, demonstrated very high NPV. Removal of a penicillin allergy label in a large majority of currently mislabeled patients has substantial personal and public health implications.
KW - Allergy
KW - Amoxicillin
KW - Penicillin
KW - Penicilloate
KW - Penicilloyl polylysine
KW - Penilloate
KW - Skin testing
UR - http://www.scopus.com/inward/record.url?scp=85064255772&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2019.02.040
DO - 10.1016/j.jaip.2019.02.040
M3 - Article
C2 - 30878711
AN - SCOPUS:85064255772
SN - 2213-2198
VL - 7
SP - 1876-1885.e3
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 6
ER -